Z. Ian Hu, M.D., Ph.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2015 | Stony Brook University of Medicine, Stony Brook, NY, USA, MD, Medicine |
| 2015 | Stony Brook University of Medicine, Stony Brook, NY, USA, PHD, Medicine |
| 2006 | Brown University, Providence, RI, USA, ScB, Biology |
Board Certifications
| 2020 | ABIM Medical Oncology |
| 2018 | ABIM Internal Medicine |
Honors & Awards
| 2015 | United States Public Health Service Excellence |
| 2007 | NIH Medical Scientist Training Fellowship |
| 2006 | Karen T. Romer Undergraduate Teaching and Research Award |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Hu ZI, Link VM, Lima-Junior DS, Delaleu J, Bouladoux N, Han SJ, Collins N, Belkaid Y. Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota. Proc Natl Acad Sci U S A 119(26):e2200348119, 2022. e-Pub 2022. PMID: 35727974.
- Hu ZI, Miettinen M, Quezado M, Lebensohn AP, Aldape K, Agra M, Wagner C, Mallory Y, Hassan R, Ghafoor A. Meningiomas in Patients With Malignant Pleural Mesothelioma Harboring Germline BAP1 Mutations. J Thorac Oncol 17(3):461-466, 2022. e-Pub 2021. PMID: 34628055.
- Hu ZI, Lim KH. Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267556.
- Hu ZI, Ghafoor A, Sengupta M, Hassan R. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies. Cancer 127(7):1010-1020, 2021. e-Pub 2021. PMID: 33620732.
- Alewine C, Ahmad M, Peer CJ, Hu ZI, Lee MJ, Yuno A, Kindrick JD, Thomas A, Steinberg SM, Trepel JB, Figg WD, Hassan R, Pastan I. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Clin Cancer Res 26(4):828-836, 2020. e-Pub 2019. PMID: 31792036.
- Ho AY, Barker CA, Arnold BB, Powell SN, Hu ZI, Gucalp A, Lebron-Zapata L, Wen HY, Kallman C, D'Agnolo A, Zhang Z, Flynn J, Dunn SA, McArthur HL. A phase 2 clinical trial?assessing the?efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer 126(4):850-860, 2020. e-Pub 2019. PMID: 31747077.
- Hu ZI, Bendell JC, Bullock A, LoConte NK, Hatoum H, Ritch P, Hool H, Leach JW, Sanchez J, Sohal DPS, Strickler J, Patel R, Wang-Gillam A, Firdaus I, Yu KH, Kapoun AM, Holmgren E, Zhou L, Dupont J, Picozzi V, Sahai V, O'Reilly EM. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med 8(11):5148-5157, 2019. e-Pub 2019. PMID: 31347292.
- Hu ZI, Hellmann MD, Wolchok JD, Vyas M, Shia J, Stadler ZK, Diaz LA, O'Reilly EM. Acquired resistance to immunotherapy in MMR-D pancreatic cancer. J Immunother Cancer 6(1):127, 2018. e-Pub 2018. PMID: 30458888.
- Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin Cancer Res 24(6):1326-1336, 2018. e-Pub 2018. PMID: 29367431.
- Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 15(3):150, 2018. e-Pub 2017. PMID: 29182164.
- Hu ZI, McArthur HL. Immunotherapy in Breast Cancer: the New Frontier. Curr Breast Cancer Rep 10(2):35-40, 2018. e-Pub 2018. PMID: 29881518.
- Sahin IH, Askan G, Hu ZI, O'Reilly EM. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?. Ann Oncol 28(12):2950-2961, 2017. PMID: 28945842.
- Ho AY, Hu ZI, Mehrara BJ, Wilkins EG. Radiotherapy in the setting of breast reconstruction: types, techniques, and timing. Lancet Oncol 18(12):e742-e753, 2017. PMID: 29208440.
- Hu ZI, Ho AY, McArthur HL. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys 99(1):153-164, 2017. e-Pub 2017. PMID: 28816141.
- Hu ZI, McArthur HL, Ho AY. The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?. Curr Breast Cancer Rep 9(1):45-51, 2017. e-Pub 2017. PMID: 28344743.
- Levy B, Hu ZI, Cordova KN, Close S, Lee K, Becker D. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer. Oncologist 21(9):1121-30, 2016. e-Pub 2016. PMID: 27388233.
- Hu ZI, Schuster JA, Kudelka AP, Huston TL. Merkel Cell Carcinoma With Gastric Metastasis and Review of Literature. J Cutan Med Surg 20(3):255-8, 2016. e-Pub 2015. PMID: 26676953.
- Hu ZI, Smith DM. Cancer Screening Rates in a Student-Run Free Clinic. Ochsner J 16(1):37-40, 2016. PMID: 27046402.
- Hu ZI, Bangiyev L, Seidman RJ, Cohen JA. Dysphagia and Neck Swelling in a Case of Undiagnosed Lhermitte-Duclos Disease and Cowden Syndrome. Case Rep Oncol Med 2015:546297, 2015. e-Pub 2015. PMID: 26448889.
- Hu ZI, Kotarba AM, Van Nostrand WE. Absence of Nitric Oxide Synthase 3 Increases Amyloid β-Protein Pathology in Tg-5xFAD Mice. Neurosci Med 4(2):84-91, 2013. PMID: 24159423.
Book Chapters
- Rohs N, Hu ZI. In: Malignant Mesothelioma in Mount Sinai Expert Guides, 2018.
Grant & Contract Support
| Title: | A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen |
| Funding Source: | Compass Therapeutics, Inc |
| Role: | Principal Investigator |
| Title: | A phase 1/2 exploratory study of the TBL1 inhibitor, tegavivint (BC2059), in patients with advanced hepatocellular carcinoma |
| Funding Source: | Iterion Therapeutics |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified April 11, 2024